论文部分内容阅读
人绒毛膜促性腺激素(hCG)由胎盘滋养细胞产生。随着尿源性纯hCG以及重组hCG的出现,其已广泛用于临床人工辅助生殖技术(ART)中。近年研究发现,hCG用于体外受精/胞浆内单精子注射(IVF/ICSI)周期前预处理可以提高胚胎质量及临床妊娠结局;hCG可在黄体中期长方案及拮抗剂方案中替代黄体生成激素(LH)或卵泡刺激素(FSH)用于晚卵泡期超促排卵;同时hCG还可能通过介导免疫机制促进胚胎着床等。hCG在ART临床中起着不可替代的作用。
Human chorionic gonadotropin (hCG) is produced by placental trophoblasts. With the advent of pure urinary hCG and recombinant hCG, it has been widely used in clinical artificial reproductive technologies (ART). In recent years, it has been found that hCG can be used to improve embryo quality and clinical pregnancy outcome by pretreatment of in vitro fertilization / intracytoplasmic sperm injection (IVF / ICSI) cycle. HCG can replace luteinizing hormone in long term mid-term regimen and antagonist regimen (LH) or follicle-stimulating hormone (FSH) for late ovulation follicular phase; while hCG may also promote embryo implantation by mediating immune mechanisms. hCG plays an irreplaceable role in clinical ART.